TICKERNERD
Menu
CLMTCLMTBasic Materials · Specialty Chemicals

CLMT Stock Forecast: Calumet, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$49
+1.49% on the day

The 6 Wall Street analysts covering Calumet, Inc. hold a median 12-month price target of $45 — -8.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 79 of 100 as at 22 Aug 2026 — inside the top quartile. The factors read stronger than the Street's target implies. That gap is the story on this page.

Market cap
$4.3B
Ticker Nerd rank
79 / 100
Median analyst target
$45
Analysts covering
6
Total return, dividends reinvested
1W
+2.7%
1M
+11.0%
YTD
+146.7%
1Y
+230.3%
From 52W high
−3.5%
From 52W low
+230.3%
$15
$51
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

CLMT stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Calumet, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
79 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
98
Growth
97
Accruals
90
Issuance
84
Revisions
63
Quality
42
Volatility
35
Size
26
Value
16

Momentum (98): The shares have been drifting up relative to others.

Value (16): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

CLMT stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CLMT, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$10$20$30$40$50$60Oct 25Jan 26Apr 26Jul 26CLMTHigh $60Median $45Low $26

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says6 analysts
2 Buy4 Hold0 Sell
Low $26Median $45High $60

The green dot is the last close — the median target sits −8.2% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 4 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
18 Aug 2026Goldman SachsMaintainsNeutral$40 → $45
12 Aug 2026TD CowenMaintainsHold$34 → $40
30 July 2026Goldman SachsMaintainsNeutral$36 → $40
30 July 2026Goldman SachsMaintainsNeutral—
30 Mar 2026HC Wainwright & Co.MaintainsBuy$33 → $60
30 Mar 2026HC Wainwright & Co.MaintainsBuy—
12 Mar 2026Goldman SachsMaintainsBuy—
30 Jan 2026Goldman SachsMaintainsBuy—
10 Nov 2025HC Wainwright & Co.ReiteratesBuy—
22 Oct 2025Goldman SachsMaintainsBuy—
12 Aug 2025UBSMaintainsNeutral—
14 May 2025Wells FargoMaintainsOverweight—
13 May 2025B of A SecuritiesInitiatesBuy—
30 Apr 2025Goldman SachsMaintainsBuy—
9 Apr 2025Wells FargoMaintainsOverweight—
17 Mar 2025UBSUpgradeNeutral—
5 Mar 2025Wells FargoMaintainsOverweight—
3 Mar 2025HC Wainwright & Co.ReiteratesBuy—
12 Feb 2025HC Wainwright & Co.ReiteratesBuy—
4 Feb 2025UBSDowngradeSell—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CLMT appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

CLMT analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+54.8%
Analysts raising
1
Analysts cutting
0
Fundamentals

Calumet, Inc. (CLMT) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
26.7×

Cheaper than 30% of US stocks

Price / sales
0.9×

Cheaper than 71% of US stocks

Price / book
−4.8×

Cheaper than 97% of US stocks

EV / EBITDA
81.8×

Cheaper than 3% of US stocks

Growth & margins
Revenue growth (YoY)
40.8%

Higher than 83% of US stocks

Earnings growth (YoY)
40.8%

Higher than 72% of US stocks

Gross margin
1.3%

Higher than 5% of US stocks

Operating margin
−4.6%

Higher than 28% of US stocks

Net margin
−3.0%

Higher than 26% of US stocks

Returns & dividend
Return on equity
6.9%

Higher than 57% of US stocks

Return on assets
−1.3%

Higher than 39% of US stocks

Dividend yield
5.6%

Higher than 84% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

CLMT vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelSpecialty Chemicals
CompanyMarket capTKN rank
CLMTCalumet, Inc.$4.3B
79
AVNTAvient Corp.$4.1B
94
CBTCabot Corp.$4.5B
86
PRMPerimeter Solutions, Inc.$5.1B
21
ASHAshland, Inc.$3.3B
85
SXTSensient Technologies Corp.$5.7B
66
FULH.B. Fuller Co.$3.2B
91

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Calumet, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest CLMT news & analysis

Calumet Is Quietly Ramping Up

Seeking Alpha · 12 Aug 2026positive

Calumet reported strong Q2 results with adjusted EBITDA of $159M, beating estimates of $116M, driven by robust Specialty Brands performance and early SAF production at MRL. The company continues to generate strong cash flow, enabling rapid debt reduction.

Why it matters — CLMT watchers would note the better-than-expected quarterly earnings, strong cash generation exceeding $1 per share per month, and early progress on the MaxSAF renewable energy initiative at Montana Renewables.

Why Calumet Stock Is Rocketing Higher Today

The Motley Fool · 10 Aug 2026positive

Calumet stock rose after Bank of America raised its price target on the company. The company also retired debt in Q2 2026, supported by stronger free cash flow.

Why it matters — A price-target increase from a major bank and debt reduction via improved cash flow are both signs of strengthening financial health for Calumet.

Calumet, Inc. (CLMT) Q2 2026 Earnings Call Transcript

Seeking Alpha · 7 Aug 2026neutral

A transcript of Calumet, Inc.'s Q2 2026 earnings call was published on Seeking Alpha, covering the company's quarterly results discussion. No further details from the call are included in the item.

Why it matters — A CLMT watcher would care because the earnings call transcript is a key primary source for management's commentary on quarterly performance.

Calumet Q2 Earnings Call Highlights

MarketBeat · 7 Aug 2026positive

Calumet reported second-quarter adjusted EBITDA with tax attributes of $175 million. Strong performance in its Specialty Products and Solutions business helped offset downtime related to planned turnarounds and the first phase of the MaxSAF 150 expansion at Montana Renewables.

Why it matters — CLMT watchers would care because the results show its Specialty Products business helped offset operational downtime while progress on the MaxSAF 150 expansion continues at Montana Renewables.

Calumet Reports Second Quarter 2026 Results

PRNewsWire · 7 Aug 2026positive

Calumet reported second quarter 2026 results with a net loss of $(95.9) million, or $(1.09) per share, driven by non-cash RINs and other mark-to-market items, while Adjusted EBITDA with Tax Attributes was $175.2 million. The company completed the first phase of its Montana Renewables MaxSAF 150 expansion, retired $115 million of debt in July, and cited strong Specialty Products & Solutions results.

Why it matters — CLMT watchers would care because the report highlights completion of the Montana Renewables SAF expansion, continued deleveraging through July debt retirement, and strong specialty-segment adjusted results despite a headline net loss.

FAQ

Frequently asked questions about CLMT stock

What is the CLMT stock price forecast for 2026-2027?

The 6 Wall Street analysts covering Calumet, Inc. have a median 12-month price target of $45, with estimates ranging from $26 to $60. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is CLMT stock a buy right now?

Of the 6 analysts covering Calumet, Inc., 2 rate it a Buy, 4 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Calumet, Inc. 79 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CLMT?

As at 22 Aug 2026, Calumet, Inc. ranks 79 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (98 of 100).

Will CLMT stock go up?

No one can know that. What the data says: the median 12-month target from 6 analysts implies -8.2% from the last close, and Ticker Nerd's factor model ranks Calumet, Inc. 79 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the CLMT stock forecast for 2030?

No analyst covering Calumet, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CLMT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $26 to $60 over the next 12 months.

How has CLMT stock performed over the past year?

Calumet, Inc. returned +230.3% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Calumet, Inc. do?

Calumet, Inc. is a leading manufacturer, formulator, and marketer of a diversified portfolio of specialty branded products serving consumer-facing and industrial markets across North America.

What is the latest news on CLMT?

The most recent item we track (Seeking Alpha, 12 Aug 2026): "Calumet Is Quietly Ramping Up". Calumet reported strong Q2 results with adjusted EBITDA of $159M, beating estimates of $116M, driven by robust Specialty Brands performance and early SAF production at MRL. The company continues to generate strong cash flow, enabling rapid debt reduction.

Company

About Calumet, Inc.

Calumet, Inc. is a leading manufacturer, formulator, and marketer of a diversified portfolio of specialty branded products serving consumer-facing and industrial markets across North America. The company operates through key divisions including Specialty Products and Solutions, Performance Brands, and Montana Renewables. Specialty Products and Solutions produces high-quality specialty oils such as DRAKEOL, HYPERTECH, PAROL, and PENPURE; base oils like CALICE, CALPAR, and CALVIS; solvents including CALSIA, CALTANE, and DRAKESOL; waxes under CALUMET WAX and TitanWax; and esters. The Performance Brands division focuses on premium finished lubricants, chemicals, and engineered fuels, featuring renowned brands like BEL-RAY, ROYAL PURPLE, and TRUFUEL. Montana Renewables specializes in producing sustainable aviation fuel, contributing to the renewable energy sector with clean and reliable solutions. Calumet, Inc. plays a vital role in the oil and gas refining and marketing industry, particularly in petroleum refining, by delivering innovative products tailored to customer needs in energy, transportation, and manufacturing sectors. Incorporated in 1919 and headquartered in Indianapolis, Indiana, the company emphasizes partnerships to provide customized solutions for complex industrial challenges.

CEO Mr. Louis Todd Borgmann · 1,540 employees · United States · https://www.calumet.com